Neurocrine Biosciences (NBIX) Competitors $145.23 -0.43 (-0.30%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$145.18 -0.05 (-0.04%) As of 09/19/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. BIIB, UTHR, INCY, BMRN, EXAS, EXEL, MDGL, IONS, HALO, and RGENShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Madrigal Pharmaceuticals Ionis Pharmaceuticals Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do insiders & institutionals have more ownership in BIIB or NBIX? 87.9% of Biogen shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate BIIB or NBIX? Biogen presently has a consensus target price of $181.65, suggesting a potential upside of 27.48%. Neurocrine Biosciences has a consensus target price of $160.26, suggesting a potential upside of 10.35%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.85 Which has more risk and volatility, BIIB or NBIX? Biogen has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Does the media refer more to BIIB or NBIX? In the previous week, Biogen had 8 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 23 mentions for Biogen and 15 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.52 beat Biogen's score of 1.07 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 14 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings and valuation, BIIB or NBIX? Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.16$1.63B$10.4613.62Neurocrine Biosciences$2.51B5.74$341.30M$3.3842.97 Is BIIB or NBIX more profitable? Biogen has a net margin of 15.31% compared to Neurocrine Biosciences' net margin of 13.88%. Biogen's return on equity of 13.85% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Neurocrine Biosciences 13.88%13.22%9.39% SummaryNeurocrine Biosciences beats Biogen on 9 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.40B$2.53B$5.77B$10.45BDividend YieldN/A55.05%5.61%4.57%P/E Ratio42.9723.0280.5026.82Price / Sales5.74484.85456.1891.67Price / Cash42.97172.2337.6661.43Price / Book5.685.3515.756.39Net Income$341.30M$32.95M$3.30B$271.80M7 Day Performance2.37%0.90%5.35%3.51%1 Month Performance7.36%4.71%7.28%9.58%1 Year Performance22.71%-2.98%80.79%28.53% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.4877 of 5 stars$145.23-0.3%$160.26+10.4%+22.7%$14.40B$2.51B42.971,800Positive NewsHigh Trading VolumeBIIBBiogen4.6808 of 5 stars$141.35+0.5%$185.74+31.4%-28.5%$20.72B$9.68B13.517,605Positive NewsAnalyst DowngradeUTHRUnited Therapeutics4.6499 of 5 stars$394.62-1.5%$429.62+8.9%+18.3%$17.80B$2.88B15.401,305Trending NewsInsider TradeINCYIncyte4.7711 of 5 stars$86.56-0.1%$82.53-4.7%+31.6%$16.90B$4.24B19.672,617Trending NewsAnalyst ForecastShort Interest ↓BMRNBioMarin Pharmaceutical4.978 of 5 stars$56.38-2.4%$92.04+63.3%-23.1%$10.83B$2.85B16.733,040Positive NewsShort Interest ↑EXASExact Sciences4.7804 of 5 stars$53.89+0.1%$67.05+24.4%-23.9%$10.20B$2.76B-9.927,000Positive NewsShort Interest ↓EXELExelixis4.6541 of 5 stars$37.69-0.5%$44.06+16.9%+51.8%$10.15B$2.17B18.121,147Positive NewsAnalyst UpgradeMDGLMadrigal Pharmaceuticals3.9549 of 5 stars$453.80+4.8%$471.13+3.8%+88.4%$10.07B$180.13M-35.3290IONSIonis Pharmaceuticals3.9168 of 5 stars$61.00-0.4%$67.88+11.3%+42.7%$9.72B$705M-33.151,069Insider TradeAnalyst RevisionHALOHalozyme Therapeutics4.5663 of 5 stars$75.85+1.2%$67.11-11.5%+31.3%$8.87B$1.02B17.36390News CoveragePositive NewsRGENRepligen4.8701 of 5 stars$120.70-3.1%$169.55+40.5%-14.5%$6.79B$634.44M-482.781,778Positive News Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Madrigal Pharmaceuticals Competitors Ionis Pharmaceuticals Competitors Halozyme Therapeutics Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIX Stock Alerts